Method for preparing thrombin for use in a biological glue

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving blood clotting factor

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S094640, C514S021800, C604S006070

Reexamination Certificate

active

06472162

ABSTRACT:

FIELD OF THE INVENTION
The following invention relates generally to the preparation of a high specific activity thrombin enzyme from a given unit of plasma, which is sufficiently stable that it provides rapid clotting of a fibrinogen-rich solution of clotting and adhesive proteins for more than six hours when held at room temperature or lower.
BACKGROUND OF THE INVENTION
Formulation of a fibrin sealant mimics the last step of the coagulation cascade wherein the enzyme thrombin cleaves fibrinogen which is then cross-linked into a semi-rigid or flexible fibrin clot. This fibrin clot adheres to wound sites, forming a barrier to fluid leaks and generates adhesion between tissues, while providing hemostatic and healing properties to the treated site.
Presently marketed, applicant's CryoSeal™ system is a device which harvests cryoprecipitated, concentrated clotting and adhesive proteins, including fibrinogen and Factor XIII from a donor's plasma in approximately one hour. The one hour cryoprecipitation harvesting, provided by the CryoSeal™ system, compared to the 1 to 2 day cryoprecipitation process routinely practiced in Blood Banks, means that CryoSeal™ harvesting of clotting and adhesive proteins can occur right in the perioperative theater with the patient close by, thereby avoiding the need to initiate the process days in advance.
These CryoSeal™ harvested clotting and adhesive proteins, when combined with bovine or human thrombin, forms a biological glue useful for surgical hemostasis and tissue adhesion. Commercially available thrombin, however, is generally sourced from bovine or human plasma pools, so the patient would still be at risk of negative immune reactions or contamination by infectious blood born viruses and, possibly Crutzfeld-Jacobs Disease (CJD) or new variants of CJD (NVCJD). An advantage of the CryoSeal™ cryoprecipitation invention is that the harvested clotting and adhesive proteins sourced from the patient's own blood eliminates the risk of contamination by infectious blood-borne disease when these clotting and adhesive proteins are topically applied to the patient's surgical wound sites.
It has long been understood, however, that the safest condition for a surgical patient would result from a two component biological sealant preparation in which the thrombin component would be harvested from the same donor in which the clotting and adhesive protein component was harvested—forming a fully autologous biological sealant or glue.
The concept of utilizing thrombin and/or fibrinogen sourced from the patient in a medical procedure performed on that patient is not novel and was first described by Andrianova in 1974. Some twenty years later, Cederholm-Williams PCT Patent (WO94/00566—Jan. 6, 1994) describes an improved fibrin glue in which the thrombin component, which required thirteen steps, including centrifugation, and separation of intermediate precipitates and adjusting the ionic strength of the blood and pH of the plasma to prepare, would be combined with a fibrinogen component also sourced from the plasma of the same donor. However, these many preparation steps are so time consuming they become impractical for use in the perioperative theater where processing times should be less than one hour.
Three years later, in 1997, Hirsh, et al. (U.S. Pat. No. 5,643,192) follows Cederholm-Williams by teaching another method of preparing fibrin glue in which both the fibrinogen and thrombin components of a fibrin glue are sourced from the same donor's plasma. The Hirsh patent describes a method of preparing thrombin in which most of the fibrinogen in the plasma is first precipitated and removed to prepare a supernatant and then clotting the residual fibrinogen in the supernatant which is different and simpler than the method taught by Cederholm-Williams, but does not result in a commercially useful thrombin in that (see FIG. 1 of Hirsh, et al.) the thrombin provides clotting speeds of five seconds or less for only 4 minutes, and less than 10 seconds for only 47 minutes.
These clotting speeds are unsuitable to the needs of surgeons who could not plan their entire surgeries around the limitations of the Hirsh, et al. fibrin glue.
Surgeons predominately require a fast acting clotting time (<5 seconds) for hemostasis and tissue sealing or adhesion. Slow clotting biological glues (>5 seconds) will often be transported away from the wound site by oozing and bleeding before they can perform their function. A surgeon utilizing the Hirsh fibrin glue would be required to arrange his surgery so that the hemostasis and tissue sealing intended for treatment with the Hirsh fibrin glue would occur within the 4 minute window where the clotting time was less than 5 seconds, making the Hirsh invention totally impractical for most surgeries which predominantly require rapid hemostasis and tissue adhesion throughout the surgery, the time span of which could extend to six hours.
The following prior art reflects the state of the art of which applicant is aware and is included herewith to discharge applicant's acknowledged duty to disclose relevant prior art. It is stipulated, however, that none of these references teach singly nor render obvious when considered in any conceivable combination the nexus of the instant invention as disclosed in greater detail hereinafter and as particularly claimed.
U.S. PATENT DOCUMENTS
INVENTOR
U.S. PAT. NO.
ISSUE DATE
Pumphrey
  713,017
November 4,
1902
Mobley
1,614,532
January 18,
1927
Ferry, et al.
2,533,004
December 5,
1950
Wahlin
2,747,936
May 29,
1956
Clark
3,179,107
April 20,
1965
Cobey
3,223,083
December 14,
1965
Kennedy, et al.
3,236,457
February 22,
1966
Meurer, et al.
3,269,389
August 30,
1966
Venus, Jr.
3,416,737
December 17,
1968
Horn
3,467,096
September 16,
1969
Creighton, et al.
3,828,980
August 13,
1974
Green
3,942,725
March 9,
1976
Polnauer, deceased, et al.
3,945,574
March 23,
1976
Speer
4,040,420
August 9,
1977
Reinhardt, et al.
4,067,333
January 10,
1978
Kozam, et al.
4,109,653
August 29,
1978
Sugitachi, et al.
4,265,233
May 5,
1981
Schwarz, et al.
4,298,598
November 3,
1981
Redl, et al.
4,359,049
November 16,
1982
Schwarz, et al.
4,362,567
December 7,
1982
Altshuler
4,363,319
December 14,
1982
Schneider
4,374,830
February 22,
1983
Schwarz, et al.
4,377,572
March 22,
1983
Schwarz, et al.
4,414,976
November 15,
1983
Stroetmann
4,427,650
January 24,
1984
Stroetmann
4,427,651
January 24,
1984
Stroetmann
4,442,655
April 17,
1984
Zimmerman, et al.
4,453,939
June 12,
1984
Rose, et al.
4,627,879
December 9,
1986
Redl, et al.
4,631,055
December 23,
1986
Sakamoto, et al.
4,655,211
April 7,
1987
Silbering, et al.
4,696,812
September 29,
1987
Alterbaum
4,714,457
December 22,
1987
Koizumi, et al.
4,734,261
March 29,
1988
Eibl, et al.
4,735,616
April 5,
1988
Saferstein, et al.
4,752,466
June 21,
1988
Wolf, et al.
4,767,416
August 30,
1988
Skorka, et al.
4,826,048
May 2,
1989
Davis
4,842,581
June 27,
1989
Miller, et al.
4,874,368
October 17,
1989
Avoy
4,902,281
February 20,
1990
Seelich
4,909,251
March 20,
1990
Tanaka, et al.
4,923,815
May 8,
1990
Silbering, et al.
4,965,203
October 23,
1990
Capozzi, et al.
4,978,336
December 18,
1990
Wolf, et al.
4,979,942
December 25,
1990
L'Hermite, et al.
4,987,336
January 22,
1991
La Duca
5,089,415
February 18,
1992
Kotitschke, et al.
5,099,003
March 24,
1992
Wolf, et al.
5,104,375
April 14,
1992
Capozzi, et al.
5,116,315
May 26,
1992
Nishimaki, et al.
5,130,244
July 14,
1992
Kraus, et al.
5,143,838
September 1,
1992
Crowley, et al.
5,151,355
September 29,
1992
Knighton
5,165,938
November 24,
1992
Galanakis
5,185,001
February 9,
1993
Morse, et al.
5,219,328
June 15,
1993
Fischer
5,290,259
March 1,
1994
Sierra, et al.
5,290,552
March 1,
1994
Michalski, et al.
5,304,372
April 19,
1994
Fischer
5,328,462
July 12,
1994
Lonneman, et al.
5,368,563
November 29,
1994
Linnau
5,393,666
February 28,
1995
Epstein
5,405,607
April 11,
1995
Marx
5,411,885
May 2,
1995
Kikuchi, et al.
5,443,959
August 22,
1995
Miller, et al.
5,474,540
December 12,
1995
Broly, et al.
5,474,770
Dec

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for preparing thrombin for use in a biological glue does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for preparing thrombin for use in a biological glue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparing thrombin for use in a biological glue will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2936590

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.